Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.26
IGC's Cash-to-Debt is ranked lower than
81% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. IGC: 0.26 )
Ranked among companies with meaningful Cash-to-Debt only.
IGC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.36 Max: N/A
Current: 0.26
Equity-to-Asset 0.68
IGC's Equity-to-Asset is ranked higher than
60% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. IGC: 0.68 )
Ranked among companies with meaningful Equity-to-Asset only.
IGC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.68 Max: 0.77
Current: 0.68
0.35
0.77
Piotroski F-Score: 3
Altman Z-Score: -4.98
Beneish M-Score: -2.97
WACC vs ROIC
18.35%
-20.84%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -146.08
IGC's Operating Margin % is ranked lower than
89% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.19 vs. IGC: -146.08 )
Ranked among companies with meaningful Operating Margin % only.
IGC' s Operating Margin % Range Over the Past 10 Years
Min: -389.94  Med: -45.64 Max: 6.53
Current: -146.08
-389.94
6.53
Net Margin % -120.99
IGC's Net Margin % is ranked lower than
88% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. IGC: -120.99 )
Ranked among companies with meaningful Net Margin % only.
IGC' s Net Margin % Range Over the Past 10 Years
Min: -496.83  Med: -60.08 Max: -1.48
Current: -120.99
-496.83
-1.48
ROE % -20.30
IGC's ROE % is ranked lower than
81% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. IGC: -20.30 )
Ranked among companies with meaningful ROE % only.
IGC' s ROE % Range Over the Past 10 Years
Min: -128.75  Med: -20.04 Max: 2.94
Current: -20.3
-128.75
2.94
ROA % -14.58
IGC's ROA % is ranked lower than
80% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. IGC: -14.58 )
Ranked among companies with meaningful ROA % only.
IGC' s ROA % Range Over the Past 10 Years
Min: -75.62  Med: -12.66 Max: 2.22
Current: -14.58
-75.62
2.22
ROC (Joel Greenblatt) % -32.78
IGC's ROC (Joel Greenblatt) % is ranked lower than
78% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.39 vs. IGC: -32.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IGC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -224.09  Med: -30.25 Max: 621.16
Current: -32.78
-224.09
621.16
3-Year Revenue Growth Rate -30.40
IGC's 3-Year Revenue Growth Rate is ranked lower than
94% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. IGC: -30.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IGC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -41.8 Max: 275.6
Current: -30.4
0
275.6
3-Year EBITDA Growth Rate -19.60
IGC's 3-Year EBITDA Growth Rate is ranked lower than
87% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. IGC: -19.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IGC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -70.6  Med: -57.75 Max: -19.6
Current: -19.6
-70.6
-19.6
3-Year EPS without NRI Growth Rate -19.00
IGC's 3-Year EPS without NRI Growth Rate is ranked lower than
81% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. IGC: -19.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IGC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.8  Med: -29.1 Max: 74.6
Current: -19
-69.8
74.6
GuruFocus has detected 5 Warning Signs with India Globalization Capital Inc $IGC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IGC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with IGC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:AQSZF, OTCPK:RLMD, OTCPK:PARNF, OTCPK:CYIG, OTCPK:PVCT, OTCPK:EMMBF, OTCPK:RSPI, OTCPK:ACUR, OTCPK:AOLS, OTCPK:PUFXF, NAS:DCTH, OTCPK:TRLPF, OTCPK:PTLF, OTCPK:ADMD, OTCPK:NRXCF, NAS:APRI, NAS:MYOS, OTCPK:YBAO, OTCPK:ULUR, OTCPK:CBICF » details
Traded in other countries:IGS1.Germany,
India Globalization Capital Inc is engaged in developing & commercializing a portfolio of proprietary cannabinoid based biopharmaceutical therapies for end of life supportive care, hospice care, & chronic neurological & oncological diagnosis.

India Globalization Capital, Inc. is a Maryland corporation, organized on April 29, 2005. It is a materials and construction company offering services including: civil construction of roads and highways, the construction and maintenance of high temperature cement and steel plants, operations and supply of rock aggregate and the export of iron ore to China. The Company's present and past clients include various Indian government organizations and steel mills in China. Including its subsidiaries, it has approximately 200 employees and contractors. It is focused on winning construction contracts, building out rock aggregate quarries and setting up relations and export hubs for the export of iron ore to China. India has strict environmental, occupational, health and safety regulations.

Ratios

vs
industry
vs
history
PB Ratio 1.62
IGC's PB Ratio is ranked higher than
75% of the 898 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. IGC: 1.62 )
Ranked among companies with meaningful PB Ratio only.
IGC' s PB Ratio Range Over the Past 10 Years
Min: 0.19  Med: 0.62 Max: 2.15
Current: 1.62
0.19
2.15
PS Ratio 3.69
IGC's PS Ratio is ranked lower than
59% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. IGC: 3.69 )
Ranked among companies with meaningful PS Ratio only.
IGC' s PS Ratio Range Over the Past 10 Years
Min: 0.11  Med: 1.17 Max: 7.46
Current: 3.69
0.11
7.46
Current Ratio 2.41
IGC's Current Ratio is ranked higher than
50% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. IGC: 2.41 )
Ranked among companies with meaningful Current Ratio only.
IGC' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.88 Max: 22.08
Current: 2.41
0.97
22.08
Quick Ratio 2.41
IGC's Quick Ratio is ranked higher than
62% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. IGC: 2.41 )
Ranked among companies with meaningful Quick Ratio only.
IGC' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 1.64 Max: 22.08
Current: 2.41
0.95
22.08
Days Inventory 63.65
IGC's Days Inventory is ranked higher than
77% of the 642 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. IGC: 63.65 )
Ranked among companies with meaningful Days Inventory only.
IGC' s Days Inventory Range Over the Past 10 Years
Min: 13.8  Med: 26.6 Max: 158.65
Current: 63.65
13.8
158.65
Days Sales Outstanding 117.02
IGC's Days Sales Outstanding is ranked lower than
76% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. IGC: 117.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
IGC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.19  Med: 96.13 Max: 2321.79
Current: 117.02
47.19
2321.79
Days Payable 91.31
IGC's Days Payable is ranked higher than
63% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. IGC: 91.31 )
Ranked among companies with meaningful Days Payable only.
IGC' s Days Payable Range Over the Past 10 Years
Min: 6.2  Med: 25.66 Max: 362.54
Current: 91.31
6.2
362.54

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -49.40
IGC's 3-Year Average Share Buyback Ratio is ranked lower than
93% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. IGC: -49.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IGC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -84.6  Med: -42.15 Max: 10.3
Current: -49.4
-84.6
10.3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 1.64
IGC's Price-to-Tangible-Book is ranked higher than
79% of the 830 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.52 vs. IGC: 1.64 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IGC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.25  Med: 1.05 Max: 5.13
Current: 1.64
0.25
5.13
Price-to-Median-PS-Value 3.15
IGC's Price-to-Median-PS-Value is ranked lower than
90% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. IGC: 3.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IGC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 1.08 Max: 5.26
Current: 3.15
0.11
5.26
Earnings Yield (Greenblatt) % -16.87
IGC's Earnings Yield (Greenblatt) % is ranked lower than
88% of the 1021 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.62 vs. IGC: -16.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IGC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -17.58  Med: 6.75 Max: 15.1
Current: -16.87
-17.58
15.1

More Statistics

Revenue (TTM) (Mil) $2.07
EPS (TTM) $ -0.12
Beta2.57
Short Percentage of Float0.31%
52-Week Range $0.19 - 0.67
Shares Outstanding (Mil)27.61
» More Articles for IGC

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
NetworkNewsWire Releases Exclusive Audio Interview with India Globalization Capital, Inc. (IGC) Mar 23 2017
India Globalization Capital, Inc. :IGC-US: Earnings Analysis: Q3, 2017 By the Numbers : March 21,... Mar 21 2017
IGC Files Patent for Cannabis-based Combination Therapy for Treatment of Eating Disorders Mar 21 2017
NetworkNewsWire Announces Publication that Reviews Cannabis-Pharma Companies Making Waves in the... Mar 17 2017
INDIA GLOBALIZATION CAPITAL, INC. Files SEC form 8-K/A, Financial Statements and Exhibits Feb 28 2017
INDIA GLOBALIZATION CAPITAL, INC. Financials Feb 25 2017
IGC Announces Third Quarter Financial Results Feb 21 2017
INDIA GLOBALIZATION CAPITAL, INC. Files SEC form 10-Q, Quarterly Report Feb 21 2017
INDIA GLOBALIZATION CAPITAL, INC. Files SEC form 8-K, Material Modification to Rights of Security... Feb 17 2017
India Globalization Capital Announces the Extension of Warrants’ Expiry Date and Inducement Grant... Feb 17 2017
IGC Launches Phytocannabinoid Development Committee to Secure Preclinical Initiatives for IGC-501,... Feb 13 2017
IGC Update on Iron Ore Subsidiary Jan 06 2017
INDIA GLOBALIZATION CAPITAL, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of... Jan 06 2017
India Globalization Capital, Inc. :IGC-US: Earnings Analysis: Q2, 2017 By the Numbers : November 22,... Nov 22 2016
INDIA GLOBALIZATION CAPITAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Nov 21 2016
INDIA GLOBALIZATION CAPITAL, INC. Files SEC form 10-Q, Quarterly Report Aug 16 2016
INDIA GLOBALIZATION CAPITAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 04 2016
Crexendo to Exhibit at CompTIA ChannelCon 2016 Jul 26 2016
INDIA GLOBALIZATION CAPITAL, INC. Files SEC form 10-K, Annual Report Jul 14 2016
EXEL INDUSTRIES :Third quarter 2015-2016 revenue Jun 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)